Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Articles
Rare disease research: the current and future state

Rare disease research: the current and future state

Today is Rare Disease Day – this article, which is the last in the series by Siren Interactive, is an interview between Wendy White and PPMD CEO, Pat Furlong, about the importance of rare disease research. It is estimated that 95 percent of rare diseases do not have an FDA approved therapy. As a result, research is...

Articles
Rare disease perspectives from patients and caregivers

Rare disease perspectives from patients and caregivers

Have you ever wondered what it must be like to live with a rare disease as a patient or caregiver? Watch our video to hear some first-hand accounts. We spoke with several rare disease patients and caregivers and asked them to share their personal experiences with us...

Articles
Editor’s Voice: February – rare disease awareness and top ten e-patients

Editor’s Voice: February – rare disease awareness and top te...

Take a look at what’s been happening on pharmaphorum this month, from our rare disease and patient content, to our top ten e-patients nominations to our rare disease patient video. If we can say so ourselves, what a fantastic month it’s been on pharmaphorum. Our disease focus this month has been...

Sales & Marketing

Sales & Marketing
Solution Spotlight: BrandPRO Biopharma
Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Digital

Market Access

Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Editor's Picks

  1. Boehringer forges $7bn alliance with China's SBP Group News
  2. Lilly partners with Hims & Hers on obesity drug sales
  3. UK women's health firm Theramex sold for around £2.2bn
  4. What do midterms mean for Trump's pharma and health agenda?
  5. NICE backs Keytruda/Padcev combo for bladder cancer

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more